Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Workman

Showing results (11-20 of 315) with videos related to

Pageof 32
Sort By:
Cancer Detection and Prevention|January 1, 2003
Pharmacogenomics in cancer drug discovery and development: inhibitors of the Hsp90 molecular chaperonePaul Workman
Trends in Molecular Medicine|April 27, 2004
Altered states: selectively drugging the Hsp90 cancer chaperonePaul Workman
Current Opinion in Investigational Drugs (London, England : 2000)|February 7, 2004
Strategies for treating cancers caused by multiple genome abnormalities: from concepts to cures?Paul Workman
Drug Discovery Today|August 30, 2003
Paul Workman on the challenges of cancer drug development. Interview by Katharine E. PestellPaul Workman
Cancer Chemotherapy and Pharmacology|June 24, 2003
The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperonesPaul Workman
Clinical Advances in Hematology & Oncology : H&O|November 14, 2006
Using biomarkers in drug developmentPaul Workman
Current Opinion in Investigational Drugs (London, England : 2000)|July 12, 2007
Drugging the cancer genome: new challenges of infrequent and combinatorial targetsPaul Workman
Cancer Research|October 2, 2023
The NCI-60 Human Tumor Cell Line Screen: A Catalyst for Progressive Evolution of Models for Discovery and Development of Cancer DrugsPaul Workman
Advances in Experimental Medicine and Biology|September 23, 2020
Correction to: Reflections and Outlook on Targeting HSP90, HSP70 and HSF1 in Cancer: A Personal PerspectivePaul Workman
Advances in Cancer Research|July 25, 2006
Inhibitors of the HSP90 molecular chaperone: current statusSwee Sharp, Paul Workman
Pageof 32

Showing results (11-20 of 315) with videos related to

Sort By:
Pageof 32
Cancer Detection and Prevention|January 1, 2003
Pharmacogenomics in cancer drug discovery and development: inhibitors of the Hsp90 molecular chaperonePaul Workman
Trends in Molecular Medicine|April 27, 2004
Altered states: selectively drugging the Hsp90 cancer chaperonePaul Workman
Current Opinion in Investigational Drugs (London, England : 2000)|February 7, 2004
Strategies for treating cancers caused by multiple genome abnormalities: from concepts to cures?Paul Workman
Drug Discovery Today|August 30, 2003
Paul Workman on the challenges of cancer drug development. Interview by Katharine E. PestellPaul Workman
Cancer Chemotherapy and Pharmacology|June 24, 2003
The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperonesPaul Workman
Clinical Advances in Hematology & Oncology : H&O|November 14, 2006
Using biomarkers in drug developmentPaul Workman
Current Opinion in Investigational Drugs (London, England : 2000)|July 12, 2007
Drugging the cancer genome: new challenges of infrequent and combinatorial targetsPaul Workman
Cancer Research|October 2, 2023
The NCI-60 Human Tumor Cell Line Screen: A Catalyst for Progressive Evolution of Models for Discovery and Development of Cancer DrugsPaul Workman
Advances in Experimental Medicine and Biology|September 23, 2020
Correction to: Reflections and Outlook on Targeting HSP90, HSP70 and HSF1 in Cancer: A Personal PerspectivePaul Workman
Advances in Cancer Research|July 25, 2006
Inhibitors of the HSP90 molecular chaperone: current statusSwee Sharp, Paul Workman
Pageof 32